Oslo, 10 June 2020: The  board of directors of Navamedic ASA (the “Company”), has on 9 June 2020, in accordance with the authorisation granted to it by the general meeting on 3 June 2020, resolved to increase the Company’s share capital by minimum NOK 0.74 and maximum NOK 34,687.50 by issuance of minimum 1 and maximum 46,875 new shares, each with a nominal value of NOK 0.74, in order to facilitate the completion of an exercise period for the 46,875 vested share options under the Company’s 2018 option program.

The exercise period shall not commence prior to the completion of the ongoing subsequent offering in the Company (which will be deemed completed upon the delivery of the offer shares to the investors) and shall expire no later than 16.30 hours (CET) on 3 July 2020.

The share capital increase will be registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret) as soon as practically possible after the exact amount of the capital increase has been determined.

For further information, please contact:

Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a preferred, full-service provider of high-quality healthcare products to hospitals and  pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.